Shin Nippon Biomedical Laboratories, Ltd. (2395.T)

JPY 1537.0

(-1.22%)

Market Cap (In JPY)

63.98 Billion

Revenue (In JPY)

26.45 Billion

Net Income (In JPY)

5.53 Billion

Avg. Volume

347.7 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
970.0-1996.0
PE
-
EPS
-
Beta Value
-0.041
ISIN
JP3379950003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
Employee Count
-
Website
https://www.snbl.co.jp
Ipo Date
2004-03-08
Details
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.